ArticleScientific reports2025
Phytochemical analysis and enzyme inhibition of Origanum dictamnus L essential oil through in vitro and in silico methods.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GB5, a synergistic phytotherapy for type 2 diabetes mellitus management: an integrated polyherbal approach from phytochemical profiling to network pharmacology.BMC complementary medicine and therapies · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Origanum dictamnus L., is an aromatic plant belonging to Lamiaceae family. The aim of this study was to evaluate whether and how O. dictamnus essential oil (EO) showed inhibitory activity against enzymes associated with the Central Nervous System disorders and human metabolism. The EO was analyzed by GC/MS. Enzyme inhibitory activity against cholinesterases, tyrosinase, α-amylase, α-glucosidase and lipase were investigated. Lineweaver-Burk plots were constructed to study the kinetic parameters of the inhibitory activity. The interactions between the main constituents of the EO and enzymes were further analyzed through an in silico molecular docking study. The EO was mainly composed by carvacrol and p-cymene. The enzymatic assays showed inhibitory activities dependent on the EO concentrations. The type of inhibition observed was mixed for acetylcholinesterase, α-glucosidase, and lipase; competitive for butyrylcholinesterase; and non-competitive for tyrosinase. O. dictamnus EO could be used as supplement for management of metabolic and neurological disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.